The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Eikon Therapeutics; Merck; Moderna Therapeutics
Stock and Other Ownership Interests - Eikon Therapeutics; Merck; Moderna Therapeutics
Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.
 
Lorenza Rimassa
Honoraria - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb Italy; Eisai; Gilead Sciences; Incyte; Ipsen; Lilly; Merck Serono; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; ArQule; AstraZeneca; Basilea; Baxter; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Elevar Therapeutics; Exelixis; Genenta Science; Hengrui Therapeutics; Incyte; Ipsen; IQvia; Italfarmaco; Jazz Pharmaceuticals; Lilly; Merck Sharp & Dohme; Nerviano Medical Sciences; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Oncology; Zymeworks
Research Funding - Agios (Inst); ARMO BioSciences (Inst); ArQule (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Eisai (Inst); Exelixis (Inst); Exelixis/Ipsen (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Nerviano Medical Sciences (Inst); Roche; Zymeworks (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Ipsen
 
Daneng Li
Consulting or Advisory Role - AstraZeneca; Delcath Systems; Eisai; Exelixis; Genentech; Merck; Sumitomo Pharma Oncology; Tersera; TransThera Biosciences
Speakers' Bureau - Eisai; Exelixis; Ipsen; SERVIER; Tersera
Research Funding - AstraZeneca (Inst); Brooklyn ImmunoTherapeutics (Inst)
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boston Scientific; Chugai Pharma; Eisai; Guardant Health; Lilly Japan; MSD; Novartis; Roche; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Mark Yarchoan
Leadership - Adventris Pharmaceuticals
Stock and Other Ownership Interests - Adventris Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Genentech/Roche; Hepion Pharmaceuticals; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Merck
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Thibaud Kossler
No Relationships to Disclose
 
Ho-Yeong Lim
Leadership - Korean Society of Medical Oncology (KSMO)
Honoraria - Bayer; Eisai; Roche
Other Relationship - AstraZeneca; Bayer; Eisai; Ipsen; Roche
 
Mariusz Kwiatkowski
No Relationships to Disclose
 
Ting-Tsung Chang
No Relationships to Disclose
 
Jee Hyun Kim
Honoraria - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; Roche; Roche; Sanofi
Consulting or Advisory Role - Bixink; Daiichi Sankyo/Astra Zeneca; Eisai; Everest Medicine; MSD; Roche; Yuhan
Research Funding - Eisai (Inst); Ono Pharmaceutical (Inst); Roche (Inst)
 
Andrea Casadei-Gardini
No Relationships to Disclose
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); EA Pharma (Inst); Eisai (Inst); GE Healthcare (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Zhenggang Ren
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme
 
Maria Varela Calvo
Honoraria - Bayer Schering Pharma; Boston Scientific; Eisai/MSD
Consulting or Advisory Role - Eisai/MSD; Roche Pharma AG
Speakers' Bureau - Eisai/MSD; Roche Molecular Diagnostics
Travel, Accommodations, Expenses - Eisai/MSD
 
Josep M Llovet
Consulting or Advisory Role - Astrazeneca; Bayer; Bluejay; Boston Scientific; Bristol Myers Squibb; Captor Therapeutics Inc; Eisai; Exelixis; Genentech; Glycotest; Ipsen; Iylon; Lilly; Merck; Mina Alpha Ltd; Nucleix; Omega Therapeutics; Roche
Research Funding - Bayer (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Bayer
 
Yayan Zhang
No Relationships to Disclose
 
Ken Hatogai
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Abby B. Siegel
Employment - Merck
Stock and Other Ownership Interests - Merck
Patents, Royalties, Other Intellectual Property - I have a patent pending related to a drug combination at Merck. I received 1$ (token) for this.
Travel, Accommodations, Expenses - Merck
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Omega Therapeutics, Inc.; Ono Pharmaceutical; Roche